In Silico Drug Design: Non-peptide Mimetics for the Immunotherapy of Multiple Sclerosis
Advances in theoretical chemistry have led to the development of various robust computational techniques employed in drug design. Pharmacophore modeling, molecular docking, and molecular dynamics (MD) simulations have been extensively applied, separately or in combination, in the design of potent molecules. The techniques involve the identification of a potential drug target (e.g., protein) and its subsequent characterization. The next step in the process comprises the development of a map describing the interaction patterns between the target molecule and its natural substrate. Once these key features are identified, it is possible to explore the map and screen large databases of molecules to identify potential drug candidates for further refinement.
Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the myelin sheath of nerve cells. The process involves the activation of encephalitogenic T cells via the formation of the trimolecular complex between the human leukocyte antigen (HLA), an immunodominant epitope of myelin proteins, and the T-cell receptor (TCR). Herein, the process for rational design and development of altered peptide ligands (APLs) and non-peptide mimetics against MS is described through the utilization of computational methods.
Key wordsPharmacophore modeling Molecular dynamics Docking Multiple sclerosis Peptide mimetics
- 1.Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683–747. https://doi.org/10.1146/annurev.immunol.23.021704.115707 CrossRefPubMedGoogle Scholar
- 3.Ben-Nun A, Kerlero de Rosbo N, Kaushansky N et al (2006) Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): prime role of MOG44F in selection and control of MOG-reactive T cells in H-2b mice. Eur J Immunol 36(2):478–493. https://doi.org/10.1002/eji.200535363 CrossRefPubMedGoogle Scholar
- 6.Wucherpfennig KW, Catz I, Hausmann S et al (1997) Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients—Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 100(5):1114–1122. https://doi.org/10.1172/Jci119622 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Pacini G, Ieronymaki M, Nuti F et al (2016) Epitope mapping of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwave-assisted synthesis of the peptide antigens and ELISA screening. J Pept Sci 22(1):52–58. https://doi.org/10.1002/psc.2839 CrossRefPubMedGoogle Scholar
- 10.Mantzourani ED, Platts JA, Brancale A et al (2007) Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87–99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response. J Mol Graph Model 26(2):471–481. https://doi.org/10.1016/j.jmgm.2007.02.004 CrossRefPubMedGoogle Scholar
- 13.Matsoukas J, Apostolopoulos V, Kalbacher H et al (2005) Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J Med Chem 48(5):1470–1480. https://doi.org/10.1021/jm040849g CrossRefPubMedGoogle Scholar
- 16.Molecular Operating Environment (MOE), 2013.08 (2017). Chemical Computing Group Inc, 1010 Sherbooke St West, Suite #910, Montreal, QC, Canada, H3A 2R7Google Scholar
- 18.Case DA, Cerutti DS, Cheatham TE et al (2017) AMBER 2017. University of California, San FranciscoGoogle Scholar
- 24.Ntountaniotis D, Vanioti M, Kordopati GG et al (2017) A combined NMR and molecular dynamics simulation study to determine the conformational properties of rat/mouse 35-55 myelin oligodendrocyte glycoprotein epitope implicated in the induction of experimental autoimmune encephalomyelitis. J Biomol Struct Dyn 35(7):1559–1567. https://doi.org/10.1080/07391102.2016.1188418 CrossRefPubMedGoogle Scholar